EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study

Srinivasan Vijay iD, Nguyen Le Hoai Bao, Dao Nguyen Vinh, Le Thanh Hoang Nhat, Do Dang Anh Thu, Nguyen Le Quang, Le Pham Tien Trieu, Hoang Ngoc Nhung, Vu Thi Ngoc Ha, Phan Vuong Khac Thai, Dang Thi Minh Ha, Nguyen Huu Lan und 4 weitere

eLife · 2024

DOI: 10.7554/elife.93243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Srinivasan Vijay und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Clinical Research Unit, Ho Chi Minh, Viet Nam. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Isoniazid, Microbial Sensitivity Tests. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotic tolerance in Mycobacterium tuberculosis reduces bacterial killing, worsens treatment outcomes, and contributes to resistance. We studied rifampicin tolerance in isolates with or without isoniazid resistance (IR). Using a minimum duration of killing assay, we measured rifampicin survival in isoniazid-susceptible (IS, n=119) and resistant (IR, n=84) isolates, correlating tolerance with bacterial growth, rifampicin minimum inhibitory concentrations (MICs), and isoniazid-resistant mutations. Longitudinal IR isolates were analyzed for changes in rifampicin tolerance and genetic variant emergence. The median time for rifampicin to reduce the bacterial population by 90% (MDK90) increased from 1.23 days (IS) and 1.31 days (IR) to 2.55 days (IS) and 1.98 days (IR) over 15–60 days of incubation, indicating fast and slow-growing tolerant sub-populations. A 6 log10-fold survival fraction classified tolerance as low, medium, or high, showing that IR is linked to increased tolerance and faster growth (OR = 2.68 for low vs. medium, OR = 4.42 for low vs. high, p-trend = 0.0003). High tolerance in IR isolates was associated with rifampicin treatment in patients and genetic microvariants. These findings suggest that IR tuberculosis should be assessed for high rifampicin tolerance to optimize treatment and prevent the development of multi-drug-resistant tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinMycobacterium tuberculosisIsoniazidMicrobial Sensitivity TestsAntitubercular AgentsDrug Resistance, BacterialLongitudinal StudiesHumansTuberculosis, Multidrug-ResistantTuberculosis

Stichwörter der Autor:innen

infectious diseasemicrobiologymycobacteriumrifampicintolerancetuberculosis

Substanzen

RifampinIsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Oxford University Clinical Research Unit, Ho Chi Minh, Viet Nam.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Theoretical Microbial Ecology, Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.
  • Cluster of Excellence Balance of the Microverse, Friedrich Schiller University Jena, Jena, Germany.
  • Pham Ngoc Thach Hospital, Ho Chi Minh, Viet Nam.
  • Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

ORCID-Profile: Srinivasan Vijay, Guy E Thwaites, Nguyen Thuy Thuong

Förderung

  • Wellcome Trust
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Vijay, S., Bao, N. L. H., Vinh, D. N., Nhat, L. T. H., Thu, D. D. A., Quang, N. L., Trieu, L. P. T., Nhung, H. N., Ha, V. T. N., Thai, P. V. K., Ha, D. T. M., Lan, N. H., Caws, M., Thwaites, G. E., Javid, B., & Thuong, N. T. (2024). Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study. eLife. https://doi.org/10.7554/elife.93243

Vancouver

Vijay S, Bao NLH, Vinh DN, Nhat LTH, Thu DDA, Quang NL, et al. Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study. eLife. 2024. doi:10.7554/elife.93243

BibTeX
@article{Vijay2024,
  author = {Vijay, Srinivasan and Bao, Nguyen Le Hoai and Vinh, Dao Nguyen and Nhat, Le Thanh Hoang and Thu, Do Dang Anh and Quang, Nguyen Le and Trieu, Le Pham Tien and Nhung, Hoang Ngoc and Ha, Vu Thi Ngoc and Thai, Phan Vuong Khac and Ha, Dang Thi Minh and Lan, Nguyen Huu and Caws, Maxine and Thwaites, Guy E and Javid, Babak and Thuong, Nguyen Thuy},
  title = {Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.93243}
}
Kostenlos starten →